Actively Recruiting
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Led by Institut Claudius Regaud · Updated on 2025-07-29
450
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the presence of double-positive circulating cells (tumor marker/CD45+) in patients with metastatic cancers across nine different cancer types, including urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, and others. This prospective, proof-of-concept pilot study aims to better understand these circulating cells before patients begin any anti-cancer treatment. The study involves patients treated at Institut Claudius Regaud or possibly other institutions and plans to enroll a total of 450 participants. Each participant will provide a blood sample before starting their metastatic cancer treatment. This sample, about 30 mL, will be analyzed using two methods: flow cytometry for all patients, and either Parsotix® or CellSearch® depending on the cancer type. Patients are grouped into cohorts based on their cancer type, with some analyzed by CellSearch® and others by Parsotix® in addition to flow cytometry. Participants will be involved in the study for one day, during which their blood sample is collected and analyzed to detect double-positive circulating cells. Researchers will measure the rate of patients presenting these cells using the two analysis techniques, with results evaluated one year after the last patient's final visit. This study does not involve treatments but focuses on understanding a potential tumor marker in metastatic cancers.
CONDITIONS
Brief Title
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervical carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
- Metastatic disease with treatment not yet started
- Age 18 years or older
- Affiliated to a French Social Security scheme
- Signed informed consent before any study procedure
You will not qualify if you...
- Patient with localized disease
- Pregnant or breast-feeding women
- Any psychological, family, geographical or sociological condition preventing compliance with study monitoring or procedures
- Patients under legal protection or who have forfeited their freedom by administrative or legal decision
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - At one time point before treatment initiation
Participants provide a blood sample before starting metastatic treatment. The sample will be analyzed to detect circulating double-positive cells using two different methods depending on cancer type.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Oncopole Claudius Regaud, IUCT-O
Toulouse, France, 31059
Actively Recruiting
Research Team
T
Thibaud VALENTIN, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here